5F-NNE1, also recognized by its aliases 5F-NNEI and 5F-MN-24, represents an indole-derived synthetic cannabinoid. This compound is believed to act as a robust agonist of the CB1 receptor and has been made available for purchase on online platforms as a designer drug. It’s noteworthy that, in connection with the related substance APINACA, which has been shown to undergo metabolic liberation of amantadine, there are suspicions that metabolic hydrolysis of the amide group within 5F-NNE1 could potentially release 1-naphthylamine, a recognized carcinogen.

IUPAC name
CAS Number1445580-60-8
PubChem CID118796566
Chemical and physical data
Molar mass374.459 g·mol−1


On November 10, 2014, Sweden’s public health agency recommended categorizing 5F-NNE1 as a potentially dangerous substance.


1. What is 5F-NNE1?

  • 5F-NNE1, 5F-NNEI and 5F-MN-24, is a synthetic cannabinoid with an indole-based structure. It has been sold as a designer drug.

2. How is 5F-NNE1 presumed to affect the body?

  • 5F-NNE1 is believed to be a potent agonist of the CB1 receptor, a vital component of the endocannabinoid system. This suggests that it may have effects similar to those of natural cannabinoids.

3. Where has 5F-NNE1 been available for purchase?

  • 5F-NNE1 has been sold online as a designer drug, making it accessible to consumers via internet platforms.

4. What concerns are associated with 5F-NNE1’s metabolic breakdown?

  • There are concerns that the metabolic hydrolysis of 5F-NNE1’s amide group may potentially release 1-naphthylamine, which is a known carcinogen. This raises safety and health-related worries regarding the substance.

5. Why did Sweden’s public health agency propose classifying 5F-NNE1 as a hazardous substance?

  • On November 10, 2014, Sweden’s public health agency recommended categorizing 5F-NNE1 as a hazardous substance. This suggests that the agency was concerned about the potential risks associated with this synthetic cannabinoid and its impact on public health and safety.

6. Is 5F-NNE1 legal in my country?

  • The legal status of 5F-NNE1 varies by country and jurisdiction. It’s essential to be aware of the specific laws and regulations in your area regarding the use, possession, and distribution of this substance.

7. Is there any safe or responsible use associated with 5F-NNE1?

  • The use of synthetic cannabinoids, including 5F-NNE1, is generally discouraged due to the potential health risks and legal restrictions. Responsible use guidelines for such substances are limited, and their safety is a concern.

8. Where can I find more information about 5F-NNE1 and its effects?

  • For comprehensive information about 5F-NNE1, its chemical properties, potential health risks, and legal status, consult reputable sources such as government health agencies, medical professionals, and substance abuse organizations.


  1. Referencing 5F-NNE1, the Southern Association of Forensic Scientists provides valuable insights. Archived records dated May 27, 2015, reveal key information on this synthetic cannabinoid, and this information was retrieved on July 24, 2015.
  2. A research study by Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, and Huestis MA, conducted in May 2015, delves into the distinctive primary metabolites produced by pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs. The study focuses on metabolite profiling for AB-PINACA and 5F-AB-PINACA. The details of this research can be found in The AAPS Journal (Volume 17, Issue 3) and are accessible via doi:10.1208/s12248-015-9721-0. Additionally, the study is identified with PMC 4406957 and PMID 25721194.
  3. For insights into the proposal to classify cannabinoids as potentially hazardous substances, you can refer to the article “Cannabinoider föreslås bli klassade som hälsofarlig vara” from Folkhälsomyndigheten, which was retrieved on July 24, 2015. This resource provides information on the potential risks associated with these substances and their impact on public health.

Leave a Comment

Your email address will not be published. Required fields are marked *